Company: HCWB
Filing Date: 2025-02-26
Form Type: DEFR14A
Source: 0001193125-25-035319
Chunk: 1

Company: HCW Biologics Inc.
Filing Date: 2025-02-26
Form: DEFR14A
Chunk 1
---
 different ratios, both of which updated disclosures are set forth on the following page. THE PROXY STATEMENT THAT HAS BEEN PRINTED AND DISTRIBUTED TO THE COMPANY’S STOCKHOLDERS WAS CORRECTED PRIOR TO PRINTING AND DOES NOT CONTAIN THE CLERICAL ERROR DESCRIBED ABOVE AND SET FORTH BELOW. Except as described above and as set forth below on the following page, this Amendment No. 1 does not supersede, modify or update any disclosure in the Proxy Statement. In addition, this Amendment No. 1 does not reflect events occurring after the date of the Proxy Statement or modify or update such disclosure that may have been affected by subsequent events. YOU SHOULD READ THIS AMENDMENT NO. 1 IN CONJUNCTION WITH THE PROXY STATEMENT, AND THE PROXY STATEMENT SHOULD BE READ IN ITS ENTIRETY, EXCEPT AS SUPERSEDED BY THE INFORMATION IN THIS AMENDMENT NO. 1 AND THE UPDATED DISCLOSURES BELOW REGARDING THE RELEVANT ITEMS ON PAGES 3 AND 13 OF THE PROXY STATEMENT. The following question and answer from page 3 of the Proxy Statement, which is included in the section of the Proxy Statement titled “QUESTIONS AND ANSWERS ABOUT PROXY MATERIALS, VOTING, AND THE MEETING,” is amended and restated in its entirety as follows:

| Q: | Who may vote at the Special Meeting? |

| A: | Stockholders of record as of the close of business on February 18, 2025, (“the Record Date”),                                                                                                                                     
 are entitled to receive notice of, to attend and participate, and to vote at the Special Meeting. At the close of business on the Record Date, there were 44,544,996 shares of our Common Stock outstanding and entitled to vote. |

The following table and accompanying footnotes from page 13 of the Proxy Statement, which is included in the section of the Proxy Statement titled “Principal Effects of a Reverse Stock Split”, is amended and restated in its entirety as follows:

|                                            |     | Number of     
 Shares of     
 Common        
 Stock Before  
 Reverse Stock 
 Split         |             |     | 1-for-20 |             |     | 1-for-30 |             |     | 1-for-40 |             |     | 1-for-50 |             |
| Authorized                                 |     |               | 250,000,000 |     |          | 250,000,000 |     |